KDNY insider filings
CHINOOK THERAPEUTICS, INC. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-08-11. Screen KDNY transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for KDNY between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — CHINOOK THERAPEUTICS, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-08-11 | 4 | Thomas Dolca — Director | Disposition to issuer (D): 13,300 · Disposition to issuer (D): 23,522 (derivative) @ $25.23 · Disposition to issuer (D): 5,948 (derivative) @ $23.19 · Disposition to issuer (D): 13,300 (derivative) @ $26.12 | EDGAR |
| 2023-08-11 | 4 | Oxtoby Andrew — Chief Commercial Officer | Disposition to issuer (D): 160,000 (derivative) @ $18.18 · Disposition to issuer (D): 40,000 (derivative) | EDGAR |
| 2023-08-11 | 4 | Krishnan Mahesh — Director | Disposition to issuer (D): 1,275 · Disposition to issuer (D): 26,600 (derivative) @ $23.26 · Disposition to issuer (D): 4,401 (derivative) | EDGAR |
| 2023-08-11 | 4 | King Andrew James — Chief Scientific Officer | Disposition to issuer (D): 19,157 · Disposition to issuer (D): 43,047 (derivative) @ $39.65 · Disposition to issuer (D): 73,047 (derivative) @ $39.58 · Disposition to issuer (D): 89,545 (derivative) @ $25.23 · Disposition to issuer (D): 60,000 (derivative) @ $24.86 · Disposition to issuer (D): 21,500 (derivative) @ $22.41 · +8 more | EDGAR |
| 2023-08-11 | 4 | Frohlich Tom — Chief Operating Officer | Disposition to issuer (D): 150,777 · Disposition to issuer (D): 43,847 (derivative) @ $39.58 · Disposition to issuer (D): 119,793 (derivative) @ $25.23 · Disposition to issuer (D): 60,000 (derivative) @ $24.86 · Disposition to issuer (D): 30,000 (derivative) @ $22.41 · Disposition to issuer (D): 100,000 (derivative) @ $27.10 · +6 more | EDGAR |
| 2023-08-11 | 4 | Jerel Davis — Director | Disposition to issuer (D): 447,013 · Disposition to issuer (D): 2,105,107 · Disposition to issuer (D): 719,104 · Disposition to issuer (D): 210,996 · Disposition to issuer (D): 23,522 (derivative) @ $25.23 · Disposition to issuer (D): 5,948 (derivative) @ $23.19 · +1 more | EDGAR |
| 2023-08-11 | 4 | Azelby Robert — Director | Disposition to issuer (D): 28,200 (derivative) @ $18.40 · Disposition to issuer (D): 7,000 (derivative) | EDGAR |
| 2023-08-11 | 4 | Greenman William Mariner — Director | Disposition to issuer (D): 23,643 · Disposition to issuer (D): 3,600 (derivative) @ $35 · Disposition to issuer (D): 8,000 (derivative) @ $0 · Disposition to issuer (D): 2,600 (derivative) @ $0 · Disposition to issuer (D): 2,600 (derivative) @ $0 · Disposition to issuer (D): 4,000 (derivative) @ $7 · +5 more | EDGAR |
| 2023-08-11 | 4 | AKKARAJU SRINIVAS — Director | Disposition to issuer (D): 3,300 · Disposition to issuer (D): 5,161,888 · Disposition to issuer (D): 23,522 (derivative) @ $25.23 · Disposition to issuer (D): 5,948 (derivative) @ $23.19 · Disposition to issuer (D): 13,300 (derivative) @ $26.12 | EDGAR |
| 2023-08-11 | 4 | GRIFFIN MICHELLE RENEE — Director | Disposition to issuer (D): 3,300 · Disposition to issuer (D): 23,522 (derivative) @ $25.23 · Disposition to issuer (D): 5,948 (derivative) @ $23.19 · Disposition to issuer (D): 13,300 (derivative) @ $26.12 | EDGAR |
| 2023-08-11 | 4 | DOBMEIER ERIC — President, CEO, Director | Disposition to issuer (D): 301,138 · Disposition to issuer (D): 353,358 (derivative) @ $39.65 · Disposition to issuer (D): 313,555 (derivative) @ $39.58 · Disposition to issuer (D): 271,647 (derivative) @ $25.23 · Disposition to issuer (D): 178,600 (derivative) @ $24.86 · Disposition to issuer (D): 300,000 (derivative) @ $27.10 · +6 more | EDGAR |
| 2023-08-11 | 4 | BJERKHOLT ERIC — Chief Financial Officer | Disposition to issuer (D): 39,371 · Disposition to issuer (D): 144,787 (derivative) @ $26.02 · Disposition to issuer (D): 21,501 (derivative) @ $24.86 · Disposition to issuer (D): 88,000 (derivative) @ $27.10 · Disposition to issuer (D): 84,000 (derivative) @ $14.73 · Disposition to issuer (D): 16,415 (derivative) · +4 more | EDGAR |
| 2023-08-01 | 4 | King Andrew James — Chief Scientific Officer | Option exercise (M): 3,333 · Sale (S): 1,168 @ $39.03 · Option exercise (M): 3,333 (derivative) @ $0 | EDGAR |
| 2023-05-31 | 4 | Haghighat Ross — Director | Option exercise (M): 3,300 · Option exercise (M): 3,300 (derivative) @ $0 | EDGAR |
| 2023-05-31 | 4 | Jerel Davis — Director | Option exercise (M): 3,300 · Option exercise (M): 3,300 (derivative) @ $0 | EDGAR |
| 2023-05-31 | 4 | Thomas Dolca — Director | Option exercise (M): 3,300 · Option exercise (M): 3,300 (derivative) @ $0 | EDGAR |
| 2023-05-31 | 4 | Greenman William Mariner — Director | Option exercise (M): 3,300 · Sale (S): 1,155 @ $23.30 · Option exercise (M): 3,300 (derivative) @ $0 | EDGAR |
| 2023-05-31 | 4 | AKKARAJU SRINIVAS — Director | Option exercise (M): 3,300 · Option exercise (M): 3,300 (derivative) @ $0 | EDGAR |
| 2023-05-31 | 4 | GRIFFIN MICHELLE RENEE — Director | Option exercise (M): 3,300 · Option exercise (M): 3,300 (derivative) @ $0 | EDGAR |
| 2023-04-26 | 4 | DOBMEIER ERIC — President, CEO, Director | Option exercise (M): 25,000 @ $0.42 · Sale (S): 23,800 @ $21.58 · Sale (S): 1,200 @ $22.26 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2023-04-19 | 4 | Jerel Davis — Director | Sale (S): 295,808 @ $20.75 | EDGAR |
| 2023-04-12 | 4 | Azelby Robert — Director | Grant/award (A): 28,200 (derivative) @ $0 · Grant/award (A): 7,000 (derivative) @ $0 | EDGAR |
| 2023-04-05 | 4 | King Andrew James — Chief Scientific Officer | Option exercise (M): 2,500 @ $0.35 · Sale (S): 5,000 @ $23.34 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2023-04-04 | 4 | Krishnan Mahesh — Director | Option exercise (M): 2,199 · Sale (S): 924 @ $23.01 · Option exercise (M): 2,199 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | Jerel Davis — Director | Sale (S): 240,000 @ $22.75 · Sale (S): 123,249 @ $22.75 · Sale (S): 36,751 @ $22.75 | EDGAR |
| 2023-03-02 | 4 | Oxtoby Andrew — Chief Commercial Officer | Grant/award (A): 160,000 (derivative) @ $0 · Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-02-15 | 4 | Frohlich Tom — Chief Operating Officer | Option exercise (M): 6,803 · Sale (S): 3,700 @ $23.75 · Option exercise (M): 6,803 (derivative) @ $0 | EDGAR |
| 2023-02-15 | 4 | King Andrew James — Chief Scientific Officer | Option exercise (M): 6,803 · Sale (S): 2,392 @ $23.75 · Option exercise (M): 6,803 (derivative) @ $0 | EDGAR |
| 2023-02-15 | 4 | DOBMEIER ERIC — President, CEO, Director | Option exercise (M): 20,248 · Sale (S): 8,097 @ $23.75 · Option exercise (M): 20,248 (derivative) @ $0 | EDGAR |
| 2023-02-15 | 4 | BJERKHOLT ERIC — Chief Financial Officer | Option exercise (M): 2,435 · Sale (S): 857 @ $23.75 · Option exercise (M): 2,435 (derivative) @ $0 | EDGAR |
| 2023-02-02 | 4 | Frohlich Tom — Chief Operating Officer | Option exercise (M): 8,333 · Sale (S): 4,566 @ $24.68 · Option exercise (M): 8,333 (derivative) @ $0 · Grant/award (A): 84,000 (derivative) @ $0 · Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2023-02-02 | 4 | King Andrew James — Chief Scientific Officer | Option exercise (M): 8,333 · Sale (S): 3,244 @ $24.68 · Option exercise (M): 8,333 (derivative) @ $0 · Grant/award (A): 104,000 (derivative) @ $0 · Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2023-02-02 | 4 | BJERKHOLT ERIC — Chief Financial Officer | Option exercise (M): 7,333 · Sale (S): 2,891 @ $24.68 · Option exercise (M): 7,333 (derivative) @ $0 · Grant/award (A): 84,000 (derivative) @ $0 · Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2023-02-01 | 4 | DOBMEIER ERIC — President, CEO, Director | Option exercise (M): 25,000 @ $0.42 · Sale (S): 25,000 @ $24.54 · Option exercise (M): 24,999 · Sale (S): 7,688 @ $24.68 · Option exercise (M): 25,000 (derivative) @ $0 · Grant/award (A): 255,150 (derivative) @ $0 · +2 more | EDGAR |
| 2023-01-04 | 4 | King Andrew James — Chief Scientific Officer | Option exercise (M): 7,500 @ $0.35 · Sale (S): 10,000 @ $25.82 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2022-12-27 | 4 | Jerel Davis — Director | Other (J): 364,587 @ $0 · Other (J): 3,600 @ $0 · Other (J): 108,715 @ $0 · Other (J): 5,865 @ $0 · Other (J): 9,465 @ $0 · Other (J): 1,646 @ $0 | EDGAR |
| 2022-12-15 | 4 | Frohlich Tom — Chief Operating Officer | Option exercise (M): 10,000 @ $0.42 · Sale (S): 10,000 @ $25.00 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2022-12-15 | 4 | DOBMEIER ERIC — President, CEO, Director | Option exercise (M): 30,000 @ $0.35 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2022-12-02 | 4 | DOBMEIER ERIC — President, CEO, Director | Gift (G): 25,000 @ $0 · Option exercise (M): 60,000 @ $0.42 · Sale (S): 30,000 @ $22.31 · Option exercise (M): 60,000 (derivative) @ $0 | EDGAR |
| 2022-12-02 | 4 | BJERKHOLT ERIC — Chief Financial Officer | Option exercise (M): 16,414 · Sale (S): 5,770 @ $22.29 · Option exercise (M): 16,414 (derivative) @ $0 | EDGAR |
| 2022-11-09 | 4 | Frohlich Tom — Chief Operating Officer | Option exercise (M): 10,000 @ $0.42 · Sale (S): 10,000 @ $22.16 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2022-10-11 | 4 | Frohlich Tom — Chief Operating Officer | Option exercise (M): 13,582 · Sale (S): 7,360 @ $19.69 · Option exercise (M): 13,582 (derivative) @ $0 | EDGAR |
| 2022-10-11 | 4 | King Andrew James — Chief Scientific Officer | Option exercise (M): 10,152 · Sale (S): 3,557 @ $19.69 · Option exercise (M): 10,152 (derivative) @ $0 | EDGAR |
| 2022-10-11 | 4 | DOBMEIER ERIC — President, CEO, Director | Option exercise (M): 30,796 · Option exercise (M): 30,796 (derivative) @ $0 | EDGAR |
| 2022-09-14 | 4 | Jerel Davis — Director | Other (J): 291,670 @ $0 · Other (J): 2,878 @ $0 · Other (J): 86,972 @ $0 · Other (J): 4,692 @ $0 · Other (J): 7,570 @ $0 · Other (J): 1,316 @ $0 · +6 more | EDGAR |
| 2022-09-06 | 4 | Thomas Dolca — Director | Purchase (P): 9,700 @ $21.22 · Purchase (P): 300 @ $21.20 | EDGAR |
| 2022-08-16 | 4 | Jerel Davis — Director | Other (J): 364,587 @ $0 · Other (J): 3,600 @ $0 · Other (J): 108,715 @ $0 · Other (J): 5,866 @ $0 · Other (J): 9,466 @ $0 · Other (J): 1,646 @ $0 | EDGAR |
| 2022-08-05 | 4 | King Andrew James — Chief Scientific Officer | Option exercise (M): 5,000 @ $0.35 · Sale (S): 5,000 @ $20 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2022-08-02 | 4 | King Andrew James — Chief Scientific Officer | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2022-07-13 | 4 | King Andrew James — Chief Scientific Officer | Option exercise (M): 5,000 @ $0.35 · Sale (S): 5,000 @ $18.09 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — CHINOOK THERAPEUTICS, INC.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2023-08-11 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-08-03 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2023-07-28 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-06-20 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-06-15 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2023-06-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-06-12 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-05-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-04-13 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-03-13 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=KDNY returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs